{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.2","upperLimit":"34.1","value":"21.3"},{"groupId":"OG001","lowerLimit":"3.2","upperLimit":"38.4","value":"8.2"},{"groupId":"OG002","lowerLimit":"4.3","upperLimit":"31.1","value":"15.6"},{"groupId":"OG003","lowerLimit":"1.8","upperLimit":"14.5","value":"3.1"},{"comment":"Median duration of response was not attained","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The upper limit was not calculable because an insufficient number of participants reached the event at the final time point for assessment","groupId":"OG005","lowerLimit":"4.5","upperLimit":"NA","value":"8.3"},{"comment":"The upper limit was not calculable because an insufficient number of participants reached the event at the final time point for assessment","groupId":"OG006","lowerLimit":"8.3","upperLimit":"NA","value":"19"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"25"},{"groupId":"OG006","value":"16"}],"units":"Participants"}],"description":"Duration of response was calculated from the documentation (date) of first response (CR, VGPR, or PR) until the date of progression or last follow-up in the subset of patients who responded. Kaplan Meier method was used to compute this outcome.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle\n\nDexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle","id":"OG000","title":"Relapsed Myeloma (<4 Prior Regimens): Low Dose"},{"description":"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle\n\nDexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle","id":"OG001","title":"Lenalidomide Refractory Myeloma: Low Dose"},{"description":"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle\n\nDexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle","id":"OG002","title":"Bortezomib/Lenalidomide Refractory/Relapsed Myeloma: Low Dose"},{"description":"Pomalidomide: 4 mg orally once daily, days 1-28 of 28 day cycle\n\nDexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle","id":"OG003","title":"Bortezomib/Lenalidomide Relapsed/Refractory Myeloma: High Dose"},{"description":"Pomalidomide: 4 mg orally once daily, days 1-28 of 28 day cycle\n\nDexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle","id":"OG004","title":"Relapsed Myeloma (< 4 Prior Regimens): High Dose"},{"description":"Pomalidomide: 4 mg orally once daily, days 1-21 of 28 day cycle\n\nDexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle","id":"OG005","title":"Relapsed/Refractory Myeloma: High Dose"},{"description":"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle\n\nDexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle","id":"OG006","title":"Relapsed Amyloidosis: Low Dose"}],"paramType":"MEDIAN","populationDescription":"Participants who achieved a partial response(PR) or better were evaluable for this analysis.","reportingStatus":"POSTED","timeFrame":"Duration of study (up to 5 years)","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}